pharma news today obesity glp-1 Prime Therapeutics' leading research shows only 1 in 12 remain on a drug for at three years Lilly and Novo defend GLP-1

And since the May 2025 deadline has already passed, healthcare professionals recommend acting now rather than waiting until your supply runs out

High switching and price sensitivity With affordability a primary barrier in the OOP market, patients may move fluidly between brands, generics, and suppliers in pursuit of the best value or simply availability

Proton pump inhibitors (PPIs) and H2-receptor antagonists, used for acid reflux, reduce stomach acid production, which can impair dietary B12 absorption, though this does not directly affect injections

Acta 104 QiW

And I met Fran, who doesnt have diabetes but is a travel writer, so of course she knows Moira McCarthy